Search
Search your stock
Analysis
Exelixis, Inc. (EXEL)
Exelixis, Inc. (EXEL)
Ranking:
Buy
Implies positive momentum
Stock Name: Exelixis, Inc.
Symbol: EXEL
Market Cap: $9.84B
Industry: Biotechnology
Sector: Healthcare
Website: https://www.exelixis.com
About Exelixis, Inc.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors Please visit their website for more information.

Overview:
Last Close: $34.45
52 Week: $20.17-$36.25
MVA50: 30.05
MVA200: 25.40
RSI: 71.60
Buy/Sell*: 67.67
1-Month change: 23.63%
3-Month change: 34.98%
*Proprietary Buy Sell Volume Indicator
Price Chart For EXEL
Financial Parameters Most Recent Quarter: (2024-Q3),2024-09-27
Revenue: $478M
Revenue Growth (YOY): 1.30%
Profit (% of Rev): 96.38%
Income (% of Rev): 24.68%
Income Growth (YOY): 11232.66%
Operating Income: $136M
Operating Cash Flow: $271M
Operating Cash Flow Growth (YoY): 131.19%
Annual Dividend Yield: 0.00%
Total Assets: $2.96B
Total Liabilities: $685M
Cash & Equivalent: $258M
Total Debt: $194M
Debt/Equity: 0.00
Quick Ratio: 3.88
Current Ratio: 3.93
Price/Book: 3.26
Price/Earnings: 15.71
EBITDA: $162M
EPS: 0.41
Our Approach

Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.

TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.

Contact @ support@theoryofstocks.com

© 2024 Stock Articles. All rights reserved.

This site uses cookies to ensure the best experience. By continuing to use this site, you agree to their use.

Click here for Cookie Policy